{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:10:45Z","timestamp":1785859845464,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03627-2","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T09:07:30Z","timestamp":1745917650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of Mirikizumab for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1891-4765","authenticated-orcid":false,"given":"Mohamed A. Abu","family":"Elainein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5338-2578","authenticated-orcid":false,"given":"Sama S.","family":"ElSherefy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8967-7191","authenticated-orcid":false,"given":"Norhan M.","family":"Yousef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0204-6461","authenticated-orcid":false,"given":"Sama M.","family":"ElKady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0212-2982","authenticated-orcid":false,"given":"Nada G.","family":"Hamam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0717-9225","authenticated-orcid":false,"given":"Abdullrahman","family":"Elgarawany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1124-8084","authenticated-orcid":false,"given":"Darin W.","family":"Aswa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2939-6064","authenticated-orcid":false,"given":"Ahmed Nour Eldin","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2749-8982","authenticated-orcid":false,"given":"Salma","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"3627_CR1","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/jgh.14872","volume":"35","author":"WY Mak","year":"2020","unstructured":"Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol. 2020;35:380\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"3627_CR2","doi-asserted-by":"publisher","first-page":"e065186","DOI":"10.1136\/bmjopen-2022-065186","volume":"13","author":"R Wang","year":"2023","unstructured":"Wang R, Li Z, Liu S, Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the global burden of disease study 2019. BMJ Open. 2023;13:e065186.","journal-title":"BMJ Open."},{"key":"3627_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","volume":"402","author":"C Le Berre","year":"2023","unstructured":"Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet Lond Engl. 2023;402:571\u201384.","journal-title":"Lancet Lond Engl"},{"key":"3627_CR4","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","volume":"380","author":"I Ord\u00e1s","year":"2012","unstructured":"Ord\u00e1s I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet Lond Engl. 2012;380:1606\u201319.","journal-title":"Lancet Lond Engl"},{"key":"3627_CR5","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","volume":"369","author":"DC Baumgart","year":"2007","unstructured":"Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet Lond Engl. 2007;369:1641\u201357.","journal-title":"Lancet Lond Engl"},{"key":"3627_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/ecco-jcc\/jjv210","volume":"10","author":"K Ikeya","year":"2016","unstructured":"Ikeya K, Hanai H, Sugimoto K, Osawa S, Kawasaki S, Iida T, et al. The ulcerative colitis endoscopic index of severity more accurately reflects clinical outcomes and long-term prognosis than the Mayo endoscopic score. J Crohns Colitis. 2016;10:286\u201395.","journal-title":"J Crohns Colitis"},{"key":"3627_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.mayocp.2018.09.013","volume":"94","author":"GP Ramos","year":"2019","unstructured":"Ramos GP, Papadakis KA. Mechanisms of disease: inflammatory bowel diseases. Mayo Clin Proc. 2019;94:155\u201365.","journal-title":"Mayo Clin Proc."},{"key":"3627_CR8","doi-asserted-by":"publisher","first-page":"F1000 Faculty R","DOI":"10.12688\/f1000research.20805.1","volume":"9","author":"RJ Porter","year":"2020","unstructured":"Porter RJ, Kalla R, Ho G-T. Ulcerative colitis: recent advances in the understanding of disease pathogenesis. F1000Res. 2020;9:F1000 Faculty Rev-294.","journal-title":"F1000Res"},{"issue":"Supplement2","key":"3627_CR9","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjac034","volume":"16","author":"GW Sewell","year":"2022","unstructured":"Sewell GW, Kaser A. Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention. J Crohns Colitis. 2022;16(Supplement2):ii3-19.","journal-title":"J Crohns Colitis"},{"key":"3627_CR10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1055\/s-0042-1758048","volume":"35","author":"J Sleiman","year":"2022","unstructured":"Sleiman J, Bassi M, Tsipotis E, Charabaty A. Medical treatment options for ulcerative colitis. Clin Colon Rectal Surg. 2022;35:428\u201336.","journal-title":"Clin Colon Rectal Surg"},{"key":"3627_CR11","doi-asserted-by":"publisher","first-page":"651415","DOI":"10.3389\/fphar.2021.651415","volume":"12","author":"B Al-Bawardy","year":"2021","unstructured":"Al-Bawardy B, Shivashankar R, Proctor DD. Novel and emerging therapies for inflammatory bowel disease. Front Pharmacol. 2021;12:651415.","journal-title":"Front Pharmacol."},{"key":"3627_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/ueg2.12275","volume":"10","author":"J Thunberg","year":"2022","unstructured":"Thunberg J, Bj\u00f6rkqvist O, Hedin CRH, Forss A, S\u00f6derman C, Bergemalm D, et al. Ustekinumab treatment in ulcerative colitis: real-world data from the Swedish inflammatory bowel disease quality register. United Eur Gastroenterol J. 2022;10:631\u20139.","journal-title":"United Eur Gastroenterol J"},{"key":"3627_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/ibd.21815","volume":"18","author":"F Magro","year":"2012","unstructured":"Magro F, Rodrigues A, Vieira AI, Portela F, Cremers I, Cotter J, et al. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Inflamm Bowel Dis. 2012;18:573\u201383.","journal-title":"Inflamm Bowel Dis"},{"key":"3627_CR14","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3390\/ijms22052719","volume":"22","author":"D Jang","year":"2021","unstructured":"Jang D, Lee A-H, Shin H-Y, Song H-R, Park J-H, Kang T-B, et al. The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int J Mol Sci. 2021;22:2719.","journal-title":"Int J Mol Sci"},{"key":"3627_CR15","first-page":"19","volume":"20","author":"B Klein","year":"2022","unstructured":"Klein B, Treudler R, Simon JC. JAK-inhibitors in dermatology \u2013 small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects. JDDG J Dtsch Dermatol Ges. 2022;20:19\u201324.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"3627_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/ibd\/izac275","volume":"30","author":"JP Gisbert","year":"2024","unstructured":"Gisbert JP, Parody-R\u00faa E, Chaparro M. Efficacy, effectiveness, and safety of Ustekinumab for the treatment of ulcerative colitis: a systematic review. Inflamm Bowel Dis. 2024;30:292\u2013302.","journal-title":"Inflamm Bowel Dis"},{"key":"3627_CR17","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s10620-021-06932-4","volume":"67","author":"S Honap","year":"2022","unstructured":"Honap S, Meade S, Ibraheim H, Irving PM, Jones MP, Samaan MA. Effectiveness and safety of Ustekinumab in inflammatory bowel disease: a systematic review and meta-analysis. Dig Dis Sci. 2022;67:1018\u201335.","journal-title":"Dig Dis Sci"},{"key":"3627_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1365-2036.2010.04234.x","volume":"31","author":"RD Cohen","year":"2010","unstructured":"Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in western countries. Aliment Pharmacol Ther. 2010;31:693\u2013707.","journal-title":"Aliment Pharmacol Ther"},{"key":"3627_CR19","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2217\/imt-2023-0012","volume":"15","author":"J Hanzel","year":"2023","unstructured":"Hanzel J, Ma C, Jairath V. Mirikizumab for the treatment of moderate to severe ulcerative colitis. Immunotherapy. 2023;15:1199\u2013208.","journal-title":"Immunotherapy"},{"key":"3627_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1124\/jpet.122.001512","volume":"387","author":"B Steere","year":"2023","unstructured":"Steere B, Beidler C, Martin A, Bright S, Kikly K, Benschop RJ. Generation and characterization of Mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23. J Pharmacol Exp Ther. 2023;387:180\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"3627_CR21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"3627_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12874-020-0897-3","volume":"20","author":"H Harrison","year":"2020","unstructured":"Harrison H, Griffin SJ, Kuhn I, Usher-Smith JA. Software tools to support title and abstract screening for systematic reviews in healthcare: an evaluation. BMC Med Res Methodol. 2020;20:7.","journal-title":"BMC Med Res Methodol"},{"key":"3627_CR23","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. https:\/\/training.cochrane.org\/handbook. Accessed 30 Aug 2024."},{"key":"3627_CR24","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, et al. Efficacy and safety of Mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology. 2020;158:537-549.e10.","journal-title":"Gastroenterology"},{"key":"3627_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cgh.2020.09.028","volume":"20","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Hibi T, D\u2019Haens GR, et al. Efficacy and safety of continued treatment with Mirikizumab in a phase 2 trial of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2022;20:105-115.e14.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3627_CR26","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, et al. Mirikizumab as induction and maintenance therapy for Ulcerative Colitis. N Engl J Med. 2023;388:2444\u201355.","journal-title":"N Engl J Med"},{"key":"3627_CR27","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1093\/ibd\/izae004","volume":"30","author":"G D\u2019Haens","year":"2024","unstructured":"D\u2019Haens G, Higgins PDR, Peyrin-Biroulet L, Sands BE, Lee S, Moses RE, et al. Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials. Inflamm Bowel Dis. 2024;30:2335.","journal-title":"Inflamm Bowel Dis."},{"key":"3627_CR28","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1053\/j.gastro.2023.11.149","volume":"166","author":"X Wang","year":"2024","unstructured":"Wang X, Bakker L, Upadhyay N, Hartz S, Treur M, Svedbom A. Cost-effectiveness analysis, of mirikizumab versus ustekinumab in advanced therapy experienced patients with moderately to severely active ulcerative colitis in the US. Gastroenterology. 2024;166:S61-2.","journal-title":"Gastroenterology"},{"issue":"Supplement1","key":"3627_CR29","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1093\/ibd\/izae020.091","volume":"30","author":"M Stargardter","year":"2024","unstructured":"Stargardter M, Upadhyay N, Raj S, Fisher D, Creveling T, Bires N, et al. Budget impact of mirikizumab-mrkz in the treatment of adult patients with moderately-to-severely active ulcerative colitis in the United States. Inflamm Bowel Dis. 2024;30(Supplement1):S43-4.","journal-title":"Inflamm Bowel Dis"},{"key":"3627_CR30","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.3390\/cells11132058","volume":"11","author":"G\u00c1 Bravo","year":"2022","unstructured":"Bravo G\u00c1, Cede\u00f1o RR, Casadevall MP, Rami\u00f3-Torrent\u00e0 L. Sphingosine-1-phosphate (S1P) and S1P signaling pathway modulators, from current insights to future perspectives. Cells. 2022;11:2058.","journal-title":"Cells."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03627-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03627-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03627-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T09:07:35Z","timestamp":1745917655000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03627-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3627"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03627-2","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"14 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Does not apply. There was no involvement of new human participants in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Does not apply. There was no involvement of new human participants in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"307"}}